Litcius/Paper detail

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals

Yugendar R. Alugubelli, Zhi Geng, Kai S. Yang, Namir Shaabani, Kaustav Khatua, R. Xinyu, Erol C. Vatansever, Chia-Chuan Cho, Yuying Ma, Jing Xiao, Lauren R. Blankenship, Ge Yu, Banumathi Sankaran, Pingwei Li, Robert D. Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu

2022European Journal of Medicinal Chemistry53 citationsDOIOpen Access PDF

Topics & Concepts

BoceprevirChemistryVirologyProteaseTelaprevirSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)EnzymeBiochemistryRibavirinMedicineInfectious disease (medical specialty)GenePathologyDiseaseGenotypeComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals | Litcius